Clinical Trials
13 trialsNCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02389751 2019-07-24
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02060253 2018-06-14
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01665937 2018-04-25
STA-9090 in Patients With Advanced Hepatocellular Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02334319 2016-07-26
Ganetespib Window of Opportunity Study in Head and Neck Cancers
Emory University
Phase 1 Terminated
NCT01554969 2016-02-22
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Emory University
Phase 1 Completed
NCT01485835 2015-10-12
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01183364 2014-09-19
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00687934 2014-09-18
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00688116 2014-09-18
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Unknown
NCT00858572 2014-09-18
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00964873 2014-09-18
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
Phase 1 Completed